

AMENDMENTS TO THE CLAIMS

Please amend claims 1, 5, 7, 12, 13, and 26 and cancel claims 2-4, 8-10 and 14-15 without prejudice as indicated below.

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims

1. (currently amended) A pharmaceutical preparation ~~for treatment of malignancies, which comprising:~~[[es]]

(a) a chemotherapeutic agent selected from the group consisting of: ~~taxol, a derivative thereof, and paclitaxel,~~ aromatase inhibitors and TRAIL TNF-related apoptosis inducing ligand; and ~~a bisphosphonate for sequential use~~

(b) 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof.

2-4. (cancelled)

5. (currently amended) A pharmaceutical preparation according to claim 1, in which the chemotherapeutic agent is paclitaxel ~~or letrozole.~~

6. (original) A pharmaceutical preparation according to claim 1, in which the chemotherapeutic agent is TNF-related apoptosis inducing ligand.

7. (currently amended) A method of treating a patient suffering from ~~a malignant disease breast cancer~~ comprising administering to the patient an effective amount of a chemotherapeutic agent selected from[[[:]] the group consisting of paclitaxel and taxol or a derivative thereof or letrozole; followed sequentially by an effective amount of ~~a bisphosphonate~~ 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid, or a pharmaceutically acceptable salt thereof.

8-10. (cancelled)

11. (original) A method according to claim 7 wherein the chemotherapeutic agent is paclitaxel.

12. (currently amended) A method according to claim 7 wherein the chemotherapeutic agent is ~~an aromatase inhibitor and is~~ letrozole.

13. (currently amended) A method of treating a patient suffering from ~~a malignant disease~~ breast cancer comprising administering to the patient an effective amount of a ~~bisphosphonate~~ 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof, followed sequentially by an effective amount of TNF-related apoptosis inducing ligand.

14-25. (cancelled)

26. (currently amended) A commercial package comprising a unit dosage form of a ~~bisphosphonate or a pharmaceutically acceptable salt thereof, or any hydrate thereof,~~ 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or a pharmaceutically acceptable salt thereof, and a unit dosage form of a chemotherapeutic agent selected from the group consisting of: ~~taxol, a derivative thereof, an~~ paclitaxel, aromatase inhibitors and ~~TRAH~~ TNF-related apoptosis inducing ligand; together with instructions for administering sequential unit doses of said chemotherapeutic agent and said ~~bisphosphonate~~ 2-imidazol-1-yl-1-hydroxyethane-1,1-diphosphonic acid or pharmaceutically acceptable salt thereof for the treatment of ~~malignant diseases~~ breast cancer.

27. (new) A pharmaceutical preparation according to claim 1, in which the chemotherapeutic agent is an aromatase inhibitor wherein the aromatase inhibitor is letrozole.